Importantly, the absence of severe hypoglycemic events in both cohorts implies that needle-free insulin delivery does not elevate the risk of hypoglycemia in the context of short-term intensive insulin therapy for T2DM patients. Here, INS is linked to type 2 diabetes mellitus.